Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akoya Biosciences Inc (AKYA)

Akoya Biosciences Inc (AKYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,863
  • Shares Outstanding, K 49,875
  • Annual Sales, $ 81,670 K
  • Annual Income, $ -55,370 K
  • EBIT $ -47 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.34
  • Price/Sales 0.70
  • Price/Cash Flow N/A
  • Price/Book 7.44

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 97.84%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.35
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +17.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +7.84%
on 04/21/25
1.3800 -20.29%
on 04/28/25
-0.1300 (-10.57%)
since 04/09/25
3-Month
1.0100 +8.91%
on 04/07/25
2.4700 -55.47%
on 02/10/25
-1.3600 (-55.28%)
since 02/07/25
52-Week
1.0100 +8.91%
on 04/07/25
4.6500 -76.34%
on 05/10/24
-3.3800 (-75.45%)
since 05/09/24

Most Recent Stories

More News
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

AKYA : 1.1000 (-3.51%)
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

AKYA : 1.1000 (-3.51%)
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

AKYA : 1.1000 (-3.51%)
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

AKYA : 1.1000 (-3.51%)
Akoya: Q4 Earnings Snapshot

Akoya: Q4 Earnings Snapshot

AKYA : 1.1000 (-3.51%)
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

AKYA : 1.1000 (-3.51%)
QTRX : 5.28 (-4.17%)
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

AKYA : 1.1000 (-3.51%)
Akoya Biosciences and NeraCare Forge Exclusive Global License Agreement for Immunoprint Test Development in Melanoma Care

Akoya Biosciences and NeraCare announced a global license agreement to develop the Immunoprint test for early-stage melanoma.Quiver AI SummaryAkoya Biosciences, Inc. and NeraCare have entered into an exclusive...

AKYA : 1.1000 (-3.51%)
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

AKYA : 1.1000 (-3.51%)
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

AKYA : 1.1000 (-3.51%)

Business Summary

Akoya Biosciences Inc. offers comprehensive single-cell imaging solutions which allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offer distinct solutions, the CODEX(R) and Phenoptics(TM)...

See More

Key Turning Points

3rd Resistance Point 1.1818
2nd Resistance Point 1.1655
1st Resistance Point 1.1327
Last Price 1.1000
1st Support Level 1.0836
2nd Support Level 1.0673
3rd Support Level 1.0345

See More

52-Week High 4.6500
Fibonacci 61.8% 3.2595
Fibonacci 50% 2.8300
Fibonacci 38.2% 2.4005
Last Price 1.1000
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar